Sedative, hypnotic, or anxiolytic-related disorders encompass problematic use of , , Z-drugs (zolpidem, zaleplon, eszopiclone), and related GABA-ergic agents, grouped together in because their pharmacology, intoxication, and withdrawal syndromes are nearly interchangeable. The class is unique in psychiatry because withdrawal can kill: untreated benzodiazepine or barbiturate withdrawal produces seizures, autonomic instability, and delirium with documented mortality. Most clinical exposure is iatrogenic, beginning with a legitimate prescription for insomnia, anxiety, or alcohol withdrawal that drifts into physiologic dependence and, in a smaller subset, a use disorder. Diagnosis rests on the same 11-criterion framework used across DSM-5-TR substance use disorders, with severity graded by symptom count. The clinical bottom line: stop these agents only with a planned taper or symptom-triggered substitution, never abruptly, and treat withdrawal as a medical emergency until proven otherwise.
Sedative-hypnotic use is common; sedative-hypnotic use disorder is not. Population surveys consistently find a wide gap between prescription exposure and DSM-defined disorder, but iatrogenic dependence after long-term use is meaningfully higher.
Prevalence
- 12-month prevalence of DSM-defined sedative, hypnotic, or anxiolytic use disorder in U.S. adults is approximately 0.3-0.5%, with lifetime prevalence near 1%.[1]
- Approximately 12-13% of U.S. adults report past-year benzodiazepine use; roughly 2% report misuse.[2]
- Long-term prescribed use (>6 months) is associated with physiologic dependence in 15-44% of patients, distinct from a use disorder.[3]
Demographics
- Female sex predominates in prescribed use; male sex predominates in nonmedical or polysubstance misuse.[1-2]
- Peak prevalence of misuse occurs in young adults (18-25), while prescribed use rises with age and is highest in adults over 65.[2]
- Older adults carry disproportionate harm from prescribed use, including falls, fractures, cognitive impairment, and motor vehicle crashes.[3]
Comorbidity and risk factors
- Co-occurring dramatically increases overdose mortality; benzodiazepines are present in roughly 30% of opioid-overdose deaths.[4]
- , other substance use disorders, panic disorder, post-traumatic stress disorder, and chronic insomnia are the strongest comorbidities.[1,3]
- Major risk factors include prior substance use disorder, chronic pain, polypharmacy, and prescription duration beyond 4 weeks.[3]
All drugs in this class are positive allosteric modulators of the , the brain's principal inhibitory ion channel. Tolerance, dependence, and withdrawal reflect compensatory downregulation of GABAergic and upregulation of glutamatergic tone.
Pharmacology
- Benzodiazepines bind the GABA-A alpha/gamma interface and increase the frequency of chloride-channel opening in the presence of GABA; they have a ceiling effect and rarely cause respiratory depression in monotherapy.[5]
- Barbiturates bind a distinct site on GABA-A, prolong chloride-channel opening, and can directly open the channel at high doses, producing dose-dependent respiratory depression without a ceiling.[5]
- Z-drugs (zolpidem, zaleplon, eszopiclone) are selective for the alpha-1 subunit, accounting for their sedative-hypnotic profile with relatively less anxiolytic effect; they share full cross-tolerance and withdrawal risk with benzodiazepines.[5-6]
Neuroadaptation and withdrawal physiology
- Chronic exposure downregulates GABA-A receptor sensitivity and upregulates glutamatergic NMDA signaling; abrupt cessation unmasks excitatory tone and produces hyperexcitability, seizures, and autonomic instability.[5-6]
- Cross-tolerance is essentially complete across the class and with alcohol, the rationale for benzodiazepine substitution in alcohol withdrawal management.[6]
Genetic and environmental contributors
- Heritability of substance use disorders broadly is estimated at 40-60%; no single gene has been replicated as specific to sedative-hypnotic use disorder.[7]
- Iatrogenic factors dominate: prescription duration, daily dose, short half-life agents, and co-prescription with opioids each independently raise risk.[3-4]
DSM-5-TR diagnoses three related conditions: sedative, hypnotic, or anxiolytic use disorder; intoxication; and withdrawal. The use disorder uses the same 11-criterion framework as other substance use disorders, with severity graded by symptom count over a 12-month period.
Use disorder criteria (DSM-5-TR)
- A problematic pattern of use leading to clinically significant impairment or distress, with at least 2 of 11 criteria within 12 months.[8]
- The 11 criteria cluster into impaired control (using more or longer than intended, unsuccessful attempts to cut down, time spent obtaining, craving), social impairment (failure to fulfill role obligations, interpersonal problems, activities given up), risky use (hazardous situations, use despite physical or psychological harm), and pharmacologic criteria (tolerance and withdrawal).[8]
- Severity: mild (2-3 criteria), moderate (4-5), severe (6 or more).[8]
- Tolerance and withdrawal criteria are NOT counted when symptoms occur during appropriate medical use under supervision.[8]
Intoxication criteria
- Recent use plus clinically significant problematic behavioral or psychological changes (inappropriate sexual or aggressive behavior, mood lability, impaired judgment) developing during or shortly after use.[8]
- At least one of: slurred speech, incoordination, unsteady gait, nystagmus, impaired cognition or memory, stupor or coma.[8]
- Not attributable to another medical condition or substance.[8]
Withdrawal criteria
- Cessation of (or reduction in) prolonged sedative-hypnotic use, with at least 2 of: autonomic hyperactivity (sweating, pulse >100), hand tremor, insomnia, nausea or vomiting, transient or illusions, , anxiety, grand mal seizures.[8]
- Symptoms cause clinically significant distress or impairment and are not better explained by another disorder.[8]
- Specifier: with perceptual disturbances when reality testing is intact; otherwise the presentation may meet criteria for substance-induced psychotic disorder.[8]
groups these conditions under "Disorders due to use of sedatives, hypnotics or anxiolytics" (6C44) and distinguishes harmful use, dependence, and intoxication using a simpler threshold-based scheme rather than the 11-criterion count.[9]
Presentation depends on whether the patient is intoxicated, in withdrawal, or in the chronic-use phase between the two. The classic teaching: intoxication looks like alcohol intoxication without the smell; withdrawal looks like alcohol withdrawal and can be just as lethal.
Intoxication
- Slurred speech, ataxia, nystagmus, and disinhibition resembling alcohol intoxication; severe intoxication progresses to stupor, respiratory depression, and coma, particularly with barbiturates or co-ingestion of opioids or alcohol.[8,10]
- Anterograde amnesia is common at therapeutic and supratherapeutic doses, especially with short-acting agents (triazolam, midazolam).[6]
- Paradoxical disinhibition, with agitation or aggression instead of sedation, occurs in roughly 1% of patients and is overrepresented in children, older adults, and patients with personality disorders.[6]
Withdrawal
- Onset depends on half-life: short-acting agents (alprazolam, lorazepam, oxazepam) produce symptoms within 6-24 hours; long-acting agents (diazepam, clonazepam, chlordiazepoxide) within 1-3 days, with peak severity often delayed to day 5-10.[6,10]
- Early symptoms mirror anxiety: tremor, insomnia, anxiety, autonomic arousal, gastrointestinal upset.[6,10]
- Severe withdrawal: grand mal seizures, hyperthermia, delirium with perceptual disturbances, and a clinical indistinguishable from severe alcohol withdrawal.[6,10]
- Untreated barbiturate or high-dose benzodiazepine withdrawal carries documented mortality; benzodiazepine withdrawal seizures occur in roughly 20-30% of patients abruptly discontinued from high-dose chronic use.[6,10]
ATSD
Sedative-hypnotic withdrawal mirrors alcohol withdrawal — Anxiety, Tremor, Seizures, Delirium. Same syndrome, different substrate.
Protracted withdrawal
- A subset of patients develop prolonged symptoms lasting weeks to months after acute withdrawal resolves: rebound anxiety, insomnia, perceptual disturbances, cognitive complaints, and dysautonomia.[11]
- Limited evidence guides management; symptom-based pharmacotherapy and behavioral interventions are the mainstays.[11]
Z-drugs are not safer than benzodiazepines for withdrawal risk. Cross-tolerance is complete, and seizures during Z-drug discontinuation are well documented.[6]
Intoxication and withdrawal mimic common medical and psychiatric emergencies. The differential is broader than "is the patient drunk?" and demands systematic exclusion before attributing presentation to sedatives.
Intoxication mimics
- Alcohol intoxication shares slurred speech, ataxia, nystagmus; co-ingestion is common and breath alcohol does not exclude sedative co-use.[10]
- Opioid intoxication causes miosis and respiratory depression; sedative monotherapy typically preserves pupils and ventilation unless very high dose.[10]
- Head injury, stroke, hypoglycemia, hepatic encephalopathy, and post-ictal state can each produce altered mentation with focal or non-focal neurologic findings; a fingerstick glucose and neurologic exam are mandatory.[10]
Withdrawal mimics
- Alcohol withdrawal is the principal mimic and frequently co-occurs; the syndromes are clinically indistinguishable and treated similarly.[12]
- Generalized anxiety disorder and panic disorder share autonomic arousal and tremor but lack the temporal link to dose reduction and rarely produce seizures.[6]
- Hyperthyroidism (and thyroid storm), pheochromocytoma, sepsis, and or neuroleptic malignant syndromes can each mimic autonomic hyperarousal; check temperature, thyroid studies, infectious workup, and recent medication changes.[10]
- toxicity produces delirium and autonomic instability with hyperthermia, dry skin, mydriasis, and urinary retention; the toxidrome is distinguishable on exam.[10]
| Feature | Sedative-hypnotic withdrawal | Alcohol withdrawal | Anticholinergic toxicity |
|---|---|---|---|
| Onset | 6 h to 7 d (half-life dependent) | 6-48 h after last drink | Minutes to hours post-exposure |
| Pupils | Normal | Normal or dilated | Markedly dilated |
| Skin | Diaphoretic | Diaphoretic | Dry, flushed |
| Seizures | Common in severe cases | Common (12-48 h) | Possible at high doses |
| First-line | Long-acting benzodiazepine taper or substitution | Symptom-triggered benzodiazepines | Supportive care; physostigmine selected cases |
Assessment combines a careful substance history with targeted exam and labs to confirm exposure, gauge severity, and exclude mimics. The single most useful question is when the last dose was taken, anchored against the agent's half-life.
History
- Quantify daily dose, duration, route, and source (prescribed, diverted, illicit) for every sedative-hypnotic, including Z-drugs and OTC sleep aids.[6]
- Screen for concurrent alcohol, opioid, and stimulant use, prior withdrawal seizures or delirium, and prior detoxification episodes.[6,10]
- Review prescriptions, prescription drug monitoring programs, and pharmacy records to corroborate self-report.[3]
Examination
- Vital signs (tachycardia, hypertension, hyperthermia), neurologic exam (nystagmus, tremor, ataxia, reflexes), and mental status are the core.[10]
- The is validated for alcohol but is commonly extrapolated to sedative-hypnotic withdrawal severity scoring; its predictive validity in benzodiazepine withdrawal is lower and clinical judgment must dominate.[12]
Laboratory and toxicology
- Urine immunoassay for benzodiazepines is unreliable: clonazepam, lorazepam, and alprazolam frequently produce false negatives because the assay targets oxazepam glucuronide; confirmation requires GC-MS or LC-MS.[13]
- Order basic metabolic panel, magnesium, phosphate, hepatic function, complete blood count, ethanol level, and pregnancy testing where appropriate; severe withdrawal triggers consideration of EKG and ammonia.[10]
- Do not order routine neuroimaging in uncomplicated withdrawal; reserve for focal neurologic findings, head trauma, atypical seizures, or persistent altered mentation despite treatment.[10]
Validated scales
- (Clinical Institute Withdrawal Assessment for Benzodiazepines) and the Benzodiazepine Withdrawal Symptom Questionnaire are available but less widely used than the CIWA-Ar.[11]
- Severity of Dependence Scale and the Benzodiazepine Dependence Self-Report Questionnaire help characterize chronic dependence in outpatient settings.[11]
Management has two arms that must be distinguished: acute treatment of intoxication or withdrawal, and longitudinal treatment of the use disorder. Withdrawal is medically urgent; the use disorder is a chronic condition managed over months to years.
Acute intoxication
- Supportive care, airway protection, and observation are the foundation; most cases resolve without specific antidote.[10]
- flumazenil 0.2 mg IV repeat to 1 mg max reverses benzodiazepine sedation but is contraindicated in chronic users (precipitates seizures), polysubstance ingestions, and patients on benzodiazepines for seizure disorders; routine use in suspected overdose is not recommended.[10]
- Activated charcoal has limited role beyond 1 hour post-ingestion and is contraindicated in patients with depressed mental status without airway protection.[10]
Pharmacotherapy
- Strong evidence supports gradual taper or substitution-and-taper with a long-acting benzodiazepine (diazepam, chlordiazepoxide, clonazepam) or phenobarbital as the standard of care for sedative-hypnotic withdrawal.[6,10,14]
- Phenobarbital protocols (oral or IV loading) have growing evidence for inpatient management of severe withdrawal and high-dose benzodiazepine dependence; advantages include broad GABA-A activity, long half-life, and self-tapering pharmacokinetics.[14]
- Outpatient tapers for therapeutic-dose dependence typically reduce by 10-25% of the original dose every 1-2 weeks, slowing as the dose decreases; rapid tapers under 2-4 weeks fail more often than slow tapers over months.[3,11]
- Limited evidence suggests adjunctive carbamazepine, valproate, or gabapentin may reduce withdrawal symptoms and facilitate taper completion, but they do not replace benzodiazepine substitution in severe withdrawal.[11]
- It is uncertain whether flumazenil infusion accelerates withdrawal in chronic users; evidence is limited to small series and the approach is not standard of care.[11]
Never discontinue chronic high-dose sedative-hypnotics abruptly. Seizures, status epilepticus, and death are documented outcomes of cold-turkey cessation.[6,10]
Psychotherapy
- combined with gradual taper outperforms taper alone for long-term abstinence in patients with prescribed-use dependence.[15]
- supports engagement, particularly in patients ambivalent about discontinuation.[15]
- Brief clinician-delivered interventions and self-help letters have moderate evidence for reducing long-term benzodiazepine use in primary care.[15]
Neuromodulation
- No neuromodulation therapy has established efficacy for sedative-hypnotic use disorder; the topic is not addressed in current major guidelines.[6,10]
Adjunctive
- Treat comorbid insomnia and anxiety with non-benzodiazepine strategies during and after taper: CBT for insomnia, / for , and behavioral activation.[15]
- Trazodone, mirtazapine, doxepin, melatonin, and ramelteon are commonly used for residual insomnia; evidence is heterogeneous and none are FDA-approved specifically for post-taper insomnia.[6,11]
- 12-step and mutual-help programs (Narcotics Anonymous, SMART Recovery) are reasonable adjuncts; specific evidence in sedative-hypnotic use disorder is limited but extrapolated from broader addiction literature.[15]
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| Long-acting benzodiazepine taper | Cochrane reviews, guideline consensus vs. abrupt cessation | Prevents seizures, reduces withdrawal severity | Prolonged sedation, dependence continuation | high | Standard of care for moderate-severe withdrawal[6,14] |
| Phenobarbital protocol | RCTs and cohort studies vs. benzodiazepine taper | Effective for high-dose and complex withdrawal; self-tapering | Respiratory depression at high doses | moderate | Growing inpatient use; requires monitoring[14] |
| Gradual outpatient taper (10-25%/1-2 wk) | Cohort and pragmatic trials vs. rapid taper | Higher long-term cessation rates | Protracted withdrawal symptoms | moderate | Slower tapers more successful at low doses[3,11] |
| CBT plus taper | RCTs vs. taper alone | Greater long-term abstinence at 12 months | Time and access constraints | moderate | Strongest psychosocial evidence[15] |
| Flumazenil for chronic-use reversal | Case series and small trials | Possible withdrawal acceleration | Seizure precipitation | very_low | Not standard of care[10-11] |
| Anticonvulsant adjuncts (carbamazepine, valproate, gabapentin) | Small RCTs vs. placebo or taper alone | Modest symptom reduction | Drug-specific toxicities | low | Adjunct only, not monotherapy[11] |
Sedative-hypnotic agents are among the most common medications implicated in iatrogenic harm in psychiatry. Adverse effects span cognitive, behavioral, and overdose domains, and the evidence base for management has important gaps.
Common adverse effects
- Daytime sedation, anterograde amnesia, slowing, and impaired driving performance are dose-dependent and worse with short-acting agents.[6]
- Falls and hip fractures are consistently elevated in older adults, with relative risk approximately 1.5-2 across observational studies.[3]
- Motor vehicle crash risk is roughly doubled in benzodiazepine users, comparable to driving with a blood alcohol concentration above legal limits.[3]
Serious and rare adverse effects
- Respiratory depression is the principal acute hazard, dose-dependent and markedly potentiated by opioids, alcohol, and other CNS depressants.[4]
- Co-prescription with opioids carries a U.S. boxed warning; observational data show 2-5 fold increases in overdose death.[4]
- Paradoxical disinhibition, complex sleep behaviors (sleep-driving, sleep-eating with Z-drugs), and pre-existing or unmasked depression occur at low frequency but with significant clinical impact.[6]
- Cognitive decline with long-term use is suggested by observational data, but causal inference is limited by confounding by indication.[3]
Limitations of the evidence
- Most withdrawal-management trials are small, short, and heterogeneous in dose, duration, and outcome definitions; head-to-head comparisons of taper regimens are scarce.[11,14]
- Long-term outcome data beyond 12 months are limited; relapse rates remain high.[15]
- Generalizability is constrained: trials enroll prescribed-use patients more readily than polysubstance or illicit users, who have worse outcomes.[15]
Risk-benefit calculations shift sharply by life stage and comorbidity. Older adults and pregnant patients warrant particular attention because the harms of both ongoing use and rapid discontinuation are amplified.
Older adults
- Benzodiazepines appear on the American Geriatrics Society Beers Criteria as potentially inappropriate due to falls, cognitive impairment, and delirium risk; deprescribing is strongly recommended when feasible.[16]
- Slower tapers (over months) and substitution to a long-acting agent first reduce withdrawal severity in this population.[16]
Pregnancy and perinatal
- First-trimester benzodiazepine exposure carries small absolute increases in oral cleft and cardiac malformation risk in some studies; data are inconsistent.[17]
- Third-trimester use is associated with neonatal floppy infant syndrome and neonatal withdrawal; abrupt maternal discontinuation, however, risks maternal seizures.[17]
- Management is individualized: continue if benefits outweigh risks, taper before delivery when possible, and coordinate with obstetrics and neonatology.[17]
Pediatric and adolescent
- Sedative-hypnotic use disorder in adolescents is most often part of a polysubstance pattern; treatment principles parallel adults with developmentally adapted psychotherapy.[1]
Co-occurring conditions
- Opioid use disorder co-occurrence demands integrated treatment; methadone or buprenorphine maintenance does not contraindicate benzodiazepine taper, and stopping one substance while continuing the other is a common pitfall.[4]
- Severe psychiatric illness (panic disorder, PTSD) requires concurrent treatment of the underlying condition during taper to reduce relapse.[15]
Outcomes are bimodal: patients with prescribed-use dependence and high motivation often achieve long-term abstinence; patients with polysubstance use and illicit-source benzodiazepines have substantially worse trajectories.
Response and remission
- Successful taper completion in prescribed-use populations reaches 40-80% across studies, with CBT adjunct improving sustained abstinence at 12 months.[15]
- Relapse rates within 12 months of cessation are estimated at 25-50%, higher in patients with comorbid substance use disorders.[15]
Mortality
- All-cause and overdose mortality are elevated in sedative-hypnotic use disorder, driven principally by co-use with opioids and alcohol.[4]
- Untreated severe withdrawal carries documented mortality; modern protocolized management has reduced but not eliminated this risk.[6,10]
Functional outcome
Sedative-hypnotic emergencies divide into overdose and withdrawal; both can be fatal and both have specific protocols. Hospitalization is required when withdrawal is severe, comorbidities complicate management, or outpatient supports are inadequate.
Hospitalization criteria
- History of withdrawal seizures or delirium, current seizures, autonomic instability, or significant medical comorbidity (cardiac, hepatic, pregnancy) warrant inpatient detoxification.[10]
- High daily doses (e.g., diazepam-equivalent >40 mg/day) or chronic polysubstance use are relative indications for inpatient management.[10]
Untreated severe sedative-hypnotic withdrawal can cause seizures, status epilepticus, and death; treat as a medical emergency.[6,10]
Overdose management
- Airway, breathing, circulation; intubation if respiratory depression is severe; reverse co-ingested opioids with naloxone.[10]
- Avoid flumazenil in chronic users, polysubstance overdose, or seizure-disorder patients; supportive care alone is generally appropriate.[10]
Suicide risk
- Suicide risk is elevated in sedative-hypnotic use disorder, particularly with co-occurring depression and alcohol use; means restriction (limited dispensing, lockboxes) is part of the safety plan.[1]
Pair every benzodiazepine prescription review with a naloxone discussion when opioids are also on the medication list. Co-prescription is the single largest modifiable risk factor for overdose death.[4]
Several long-running debates affect day-to-day prescribing and merit explicit discussion when teaching trainees.
- Whether long-term benzodiazepines cause persistent cognitive impairment remains contested; observational data suggest a signal but cannot exclude confounding by underlying anxiety, depression, or insomnia.[3]
- The optimal pace of outpatient taper is unresolved; pragmatic experience favors slow tapers over months, but high-quality comparative trials are lacking.[11]
- Phenobarbital is gaining traction for inpatient withdrawal management, but routine substitution for benzodiazepine taper remains practice-variable and guideline-inconsistent.[14]
- The role of flumazenil infusion in accelerating chronic-use withdrawal is unsettled; small studies suggest benefit, but seizure risk and the absence of large trials limit adoption.[11]
- ICD-11 and DSM-5-TR diverge on diagnostic thresholds; the clinical implications of using a dependence-based versus criterion-count model are debated.[8-9]
- DSM-5-TR diagnoses sedative, hypnotic, or anxiolytic use disorder when at least 2 of 11 criteria occur within a 12-month period; severity is mild (2-3), moderate (4-5), or severe (6+).[8]
- Tolerance and withdrawal criteria are NOT counted toward use disorder when the substance is taken as prescribed under medical supervision.[8]
- Benzodiazepines bind the GABA-A receptor at the alpha/gamma interface and increase chloride-channel opening frequency; barbiturates prolong opening duration and can open the channel directly at high doses, accounting for their greater lethality.[5]
- Z-drugs are selective for the alpha-1 subunit, share full cross-tolerance with benzodiazepines, and produce identical withdrawal risks.[5-6]
- Severe untreated sedative-hypnotic withdrawal can produce seizures, autonomic instability, delirium, and death; standard management is gradual taper or substitution with a long-acting benzodiazepine or phenobarbital.[6,10]
- Withdrawal onset is half-life dependent: short-acting agents within 6-24 hours, long-acting agents within 2-7 days with peak severity often delayed to day 5-10.[6,10]
- Flumazenil is contraindicated in chronic benzodiazepine users, polysubstance overdose, and seizure-disorder patients because it precipitates seizures.[10]
- Urine benzodiazepine immunoassays frequently miss clonazepam, lorazepam, and alprazolam; targeted assays target oxazepam glucuronide and produce false negatives.[13]
- Co-prescription of benzodiazepines with opioids carries a U.S. boxed warning and is implicated in roughly 30% of opioid overdose deaths.[4]
- The American Geriatrics Society Beers Criteria identify benzodiazepines as potentially inappropriate in older adults due to falls, cognitive impairment, and delirium risk.[16]
- Third-trimester benzodiazepine use is associated with neonatal floppy infant syndrome and neonatal withdrawal; abrupt maternal discontinuation risks maternal seizures.[17]
- CBT combined with gradual taper improves long-term abstinence rates over taper alone in prescribed-use dependence.[15]
- Outpatient tapers typically reduce by 10-25% every 1-2 weeks, slowing as the dose decreases; rapid tapers under 2-4 weeks have lower success rates.[3,11]
- Heritability of substance use disorders broadly is approximately 40-60%; no single gene is specific to sedative-hypnotic use disorder.[7]
No external funding. No conflicts of interest declared. Peer-review status: pending.
- 1.Hasin DS, Grant BF. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol. 2015;50(11):1609-1640. doi:10.1007/s00127-015-1088-0.doi:10.1007/s00127-015-1088-0.
- 2.Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97-106. doi:10.1176/appi.ps.201800321.doi:10.1176/appi.ps.201800321.
- 3.Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147-1157. doi:10.1056/NEJMra1611832.doi:10.1056/NEJMra1611832.
- 4.Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. doi:10.1136/bmj.j760.doi:10.1136/bmj.j760.
- 5.TextbookStahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
- 6.TextbookSchatzberg AF, DeBattista C. Manual of Clinical Psychopharmacology. 9th ed. Washington, DC: American Psychiatric Association Publishing; 2019.
- 7.Systematic reviewVerhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychol Med. 2015;45(5):1061-1072. doi:10.1017/S0033291714002165.doi:10.1017/S0033291714002165.
- 8.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. Washington, DC: American Psychiatric Association Publishing; 2022.
- 9.TextbookWorld Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: WHO; 2019.
- 10.TextbookBoland RJ, Verduin ML, Ruiz P. Kaplan & Sadock's Synopsis of Psychiatry. 12th ed. Philadelphia: Wolters Kluwer; 2022.
- 11.Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295-301. doi:10.1111/j.1365-2125.2012.04418.x.doi:10.1111/j.1365-2125.2012.04418.x.
- 12.GuidelineMayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144-151. doi:10.1001/jama.1997.03550020076042.doi:10.1001/jama.1997.03550020076042.
- 13.Moeller KE, Kissack JC, Atayee RS, Lee KC. Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clin Proc. 2017;92(5):774-796. doi:10.1016/j.mayocp.2016.12.007.doi:10.1016/j.mayocp.2016.12.007.
- 14.Oks M, Cleven KL, Healy L, et al. The safety and utility of phenobarbital use for the treatment of severe alcohol withdrawal syndrome in the medical ICU. J Intensive Care Med. 2020;35(9):844-850. doi:10.1177/0885066618783947.doi:10.1177/0885066618783947.
- 15.Systematic reviewDarker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev. 2015;(5):CD009652. doi:10.1002/14651858.CD009652.pub2.doi:10.1002/14651858.CD009652.pub2.
- 16.By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372.doi:10.1111/jgs.18372.
- 17.Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53(1):39-49. doi:10.1176/appi.ps.53.1.39.doi:10.1176/appi.ps.53.1.39.
More on these topics
Tobacco-Related Disorders: Diagnosis, Neurobiology, and Evidence-Based Treatment
Clinical reference on tobacco use disorder and nicotine withdrawal — diagnosis, neurobiology, and first-line pharmacologic and behavioral treatment.
Tobacco-Related DisordersSubstance-Related and Addictive DisordersStimulant-Related Disorders: Clinical Overview and Management
Evidence-based overview of stimulant use, intoxication, withdrawal, and stimulant use disorder for clinicians and trainees.
Stimulant-Related DisordersPsychosisStimulant UseOpioid-Related Disorders: Diagnosis, Pharmacotherapy, and Overdose Management
Clinical reference on opioid use disorder and opioid overdose covering DSM-5-TR diagnosis, MOUD with methadone, buprenorphine, and naltrexone, and naloxone reversal.
Opioid-Related DisordersSubstance-Related and Addictive DisordersInhalant-Related Disorders: Diagnosis, Neurotoxicity, and Clinical Management
A clinical reference on inhalant use, intoxication, and inhalant use disorder, covering neurotoxicity, assessment, and evidence-based management.
Inhalant-Related DisordersSubstance-Related and Addictive DisordersGambling Disorder: Diagnosis, Neurobiology, and Evidence-Based Management
Clinical reference on gambling disorder covering DSM-5-TR criteria, reward-circuit neurobiology, screening, and pharmacologic and psychotherapeutic management.
Gambling DisorderSubstance-Related and Addictive DisordersHallucinogen-Related Disorders: Diagnosis, Pharmacology, and Clinical Management
Clinical reference on hallucinogen intoxication, persisting perception disorder, and use disorder, with DSM-5-TR criteria and evidence-based management.
Hallucinogen-Related DisordersSubstance-Related and Addictive DisordersCannabis-Related Disorders: Intoxication, Withdrawal, Use Disorder, and Cannabis-Induced Psychosis
A clinical reference on cannabis use disorder, intoxication, withdrawal, and induced syndromes, including diagnosis, treatment, and high-yield exam points.
Cannabis-Related DisordersSubstance-Related and Addictive DisordersCaffeine-Related Disorders: Intoxication, Withdrawal, and Use Disorder
A clinical guide to DSM-5-TR caffeine intoxication and withdrawal, the proposed caffeine use disorder, and evidence-based management.
Caffeine-Related DisordersSubstance-Related and Addictive Disorders